GSK Pharma Enters Oncology in India with Cancer Therapies

GlaxoSmithKline Pharmaceuticals said on Monday it has entered the oncology segment in India with the launch of two therapies for gynaecological cancers, Jemperli (dostarlimab) and Zejula (niraparib).

Jemperli is the first and only approved PD-1 immunotherapy in India for second-line treatment of mismatch repair-deficient or microsatellite instability-high advanced or recurrent endometrial cancer.

Zejula is the only once-daily oral PARP inhibitor in India approved as a first-line monotherapy maintenance treatment for all biomarker types in advanced ovarian cancer, the company said in its filing.